Pterostilbene MicroRNA Expression Promotion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for a compound that can effectively promote the expression levels of specific microRNAs, such as miR-200c, miR-141, miR-34a, miR-16, miR-126, miR-193b, and let-7a, which are abnormally expressed in various diseases including cancer, osteoporosis, and cardiovascular diseases.
Innovation Solution
Pterostilbene is used as a microRNA expression promoting agent, either alone or in combination with oils and fats, for oral administration, to enhance the expression of the mentioned microRNAs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pterostilbene is used to promote microRNA expression, then the expression levels of specific microRNAs (miR-200c, miR-141, miR-34a, miR-16, miR-126, miR-193b, and let-7a) are improved, but the complexity of identifying and validating effective compounds increases
Solution Approach 1:
The patent changes the chemical parameter by selecting pterostilbene (a stilbene derivative) as the active compound to promote microRNA expression. This specific chemical parameter change resolves the contradiction by providing a validated compound that reliably promotes expression of multiple specific microRNAs, thereby reducing the complexity of compound identification while maintaining reliable expression promotion.
2Ease of operation
If pterostilbene is administered orally, then the ease of administration is improved, but the bioavailability and effectiveness of the compound may be reduced
Solution Approach 1:
The patent changes the physical parameter by formulating pterostilbene in combination with oils and fats, which improves its solubility and bioavailability. This parameter change enables effective oral administration while maintaining the reliability of microRNA expression promotion, thus resolving the contradiction between administration convenience and compound effectiveness.
Data Source
AI summary
The present invention relates to a microRNA expression promoting agent, containing pterostilbene, wherein the microRNA is at least one selected from the group consisting of miR-34a, miR-16, miR-126, miR-193b, and let-7a.